-

Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science

Multifaceted national initiative invites Americans to share stories of science’s impact and challenge misinformation

ST. LOUIS--(BUSINESS WIRE)--Today, on World Science Day, Bayer is proud to launch its “Science Delivers” campaign, a nationwide initiative celebrating how science delivers answers, hope, and progress for all Americans—every day, in the moments that matter most.

From the medicine that keeps us healthy to the technology that connects and helps feed us, to the innovations that give us hope for the future—science has consistently driven progress and shapes every aspect of our lives. The campaign is inspired by the idea that science delivers more than solutions—it delivers breakthroughs that heal, protect, connect, and empower.

“Science Delivers” comes at a moment when misinformation threatens to undermine America’s innovation drive and the future of such breakthroughs. At a time of uncertainty, Bayer is committed to the idea that science is a method designed to test ideas, challenge assumptions, and build knowledge over time. The campaign encourages scientists, educators, media and citizens to learn how to spot misinformation and help push back against fearmongering and pseudoscience.

The campaign’s features include a Declaration on Science appearing in select newspapers, an interactive website to engage and become part of the movement, ads promoting the campaign, and oversized, interactive “Science, Sealed, Delivered” mailboxes at select events and locations, including most recently at the World Food Prize’s 2025 Borlaug Dialogue in Des Moines, Iowa.

At each mailbox, visitors are invited to scan a QR code and drop a digital postcard, delivering their own science moment— how science has sparked change, inspired hope, or powered progress in their lives and communities. These real stories are showcased on the newly launched ScienceDelivers.com, where Americans can explore a digital mosaic of testimonials, discover how science delivers, and learn more about the scientific process and how to identify credible evidence.

The Declaration on Science – “Don’t (Just) Trust the Science” – appears in the Wall Street Journal, Washington Times and Politico and affirms the importance of an evidence-based process conducted and reviewed by independent sources:

“We must strive to be healthier, more sustainable, and focused on what innovation can bring to improve society. We must celebrate science and continue every day to innovate. To find the next cure. To find the next breakthrough.”

In addition, as part of the campaign, a new video running nationally highlights key innovations made possible by science.

The “Science Delivers” campaign will give Americans a glimpse into scientific milestones that have transformed the way we live, work and care for ourselves and our planet.

Join Us and Share Your Support for Science:

Bayer encourages everyone to engage with the "Science Delivers" campaign by sharing their stories through social media and community events to champion science and its impact. Together, let us recognize the importance of science in our lives and advocate for its vital role in shaping a better future.

For more information on the "Science Delivers" campaign, visit www.ScienceDelivers.com.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Contacts

Media Contact:
Brian Leake
Brian.Leake@Bayer.com
(314) 370-3285

Bayer

GER:BAYN

Release Versions

Contacts

Media Contact:
Brian Leake
Brian.Leake@Bayer.com
(314) 370-3285

More News From Bayer

Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy

BERLIN & BOSTON--(BUSINESS WIRE)--Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, today announced a strategic collaboration and global licensing agreement to advance a heart-targeted small interfering RNA (siRNA) therapy. The companies will collaborate to develop a siRNA-based treatment for a form of dilated cardiomyopathy, addressing a rare subset of heart disease. "We are excited to partner with Soufflé and begin exp...

Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan’s 44th Annual Healthcare Conference

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will participate in the 44th J.P. Morgan Healthcare Conference 2026 taking place from January 12–15, 2026 in San Francisco. Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Bayer’s Pharmaceuticals Division, will present updates on the company’s pharmaceutical growth strategy and pipeline advancements across its portfolio. The presentation will take place on Tuesday, January 13, 2026, from 11:15 to 11:55 PST. Investors, analysts...

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a randomized, double-blind, placebo-controlled, group-comparison trial (NCT07211685), with an extension phase, which will investigat...
Back to Newsroom